Lymphoma Diagnosis and Therapy
This discovery may be used to: Develop a simple blood test to screen Lym-1 reactivity of prospective lymphoma patients for Lym-1 treatment, replacing any need for a biopsy. Develop new antibodies that could be used in either diagnostic assays or therapeutic applications for non-Hodgkin's lymphoma.
The specific cell surface antigen for Lym-1, a murine monoclonal antibody selective for malignant B lymphocytes, has been identified as a discontinuous epitope on the beta chain of many, but not all HLA-DR subtypes, by UC Davis investigators. Lym-1 has shown promising results in targeted lymphoma radiodiagnosis and therapy.
Patent Number: US6217871B1
Application Number: US1998181896A
Inventor: Rose, Larry M. | Meares, Claude F. | O'Donnell, Robert T.
Priority Date: 28 Oct 1998
Priority Number: US6217871B1
Application Date: 28 Oct 1998
Publication Date: 17 Apr 2001
IPC Current: A61K003900 | C07K001474 | C12Q000168
US Class: 4241841 | 4241301 | 4241331 | 4241851 | 530326
Assignee Applicant: The Regents of the University of California
Title: Antigenic epitopes with LYM-1 reactivity and uses thereof
Usefulness: Antigenic epitopes with LYM-1 reactivity and uses thereof
Summary: The peptide can be used to generate antibodies to the epitope recognized by the Lym-1 antibody. These can be used to identify patients who will be responsive to a therapeutic Lym-1 antibody and to treat patients affected by non-Hodgkin's B-cell lymphoma (all claimed).
Novelty: Novel peptide epitopes recognized by the non-Hodgkin's B-cell lymphoma Lym-1 antibody, useful for generating antibodies for treating non-Hodgkin's B-cell lymphoma
診斷/治療
其他疾病
6217871
Related Technologies Tech ID/UC Case 11405/1998-009-0 Related Cases 1998-009-0
美國
